Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Thyroid cancer
Trial Status:  Active
Results 1-25 of 162 for your search:
Start Over
Total Thyroidectomy With Harmonic Scalpel®
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: CP005, NCT00385983
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-401, NCT01896479
Radiolabeled Molecules for Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Lu177-med, NCT01915485
Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 19 to 70
Sponsor: Other
Protocol IDs: USG-Vokal cord, NCT02410928
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2009-02-017, NCT01149161
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/10/0299, 2011-000144-21, Cancer Research UK, ISRCTN, NCT01398085
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: NCCCTS13-671, 1410650-1,2, NCT02418247
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2008-09-048, NCT00795782
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: H10-02695, NCT01373736
Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hyalobarrier_P3, NCT01696305
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00065, EudraCT 2013-000423-14, NCT01843062
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-A01569-34, 2012/1913, NCT01837745
Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: B-1403/242-006, NCT02112370
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: NCI
Protocol IDs: 110027, 11-C-0027, NCT01240590
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Effect of Carum Carvi on Thyroid Hormones and TSH Level
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 88498, NCT01471288
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRD 11/5-L, NCT01730638
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Phase: Phase II, Phase I
Type: Supportive care
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: SAL 2012-0584, NCT01739634
Start Over